Unraveling the prognostic significance and molecular mechanisms of HKDC1 in cancer via integrated multi-omics and experimental validation.

BACKGROUND

HKDC1 (Hexokinase Domain Containing 1), a recently identified member of the hexokinase family, has emerged as a potential oncogene with significant involvement in tumor progression, immune evasion, and cellular metabolism.

METHODS

A pan-cancer analysis was performed using TCGA, GTEx, and TIP databases. In vitro experiments, including qPCR, Western blot, CCK-8 assay, scratch assay, colony formation, and transwell assays, were conducted to evaluate HKDC1's role in cancer.

RESULTS

Bioinformatics study analyses revealed HKDC1 overexpression in 8 malignancies, correlating with a poor prognosis. Multi-dimensional analyses delineated HKDC1's immunomodulatory role, demonstrating pan-cancer correlations with immunoregulatory genes and bidirectional associations with tumor stemness. Single-cell analyses in gastric cancer identified significant interactions between HKDC1 +Mali cells and endothelial cells, fibroblasts, and immune cells, suggesting HKDC1 + malignant cells regulate immune responses and promote tumor growth. Functional validation showed HKDC1 knockdown suppressed GC invasion. Epigenetically, HKDC1 regulates H3K18 lactylation to activate VCAM1, thereby driving gastric cancer proliferation.

CONCLUSION

In summary, our pan-cancer analysis identifies HKDC1 as a novel biomarker for prognosis and immunotherapy response. HKDC1 drives metabolic reprogramming via glycolysis and immune evasion by suppressing T-cell activity. In GC, HKDC1 promotes H3K18 lactylation, upregulating VCAM1 to enhance tumor progression.